Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KIT Y553_K558del TSC1 G464fs |
| Therapy | Everolimus + Ripretinib |
| Indication/Tumor Type | gastrointestinal stromal tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT Y553_K558del TSC1 G464fs | gastrointestinal stromal tumor | predicted - sensitive | Everolimus + Ripretinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Qinlock (ripretinib) and Afinitor (everolimus) resulted in stable disease with a progression-free survival of 8.5 months in a patient with recurrent gastrointestinal stromal tumor harboring KIT Y553_K558del and TSC1 G464fs (PMID: 40700673; NCT02534675). | 40700673 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40700673) | Personalized N-of-1 Combination Therapies for Advanced Gastrointestinal Stromal Tumors. | Full reference... |